HC Wainwright Boosts Earnings Estimates for Rockwell Medical

Rockwell Medical, Inc. (NASDAQ:RMTI) – HC Wainwright raised their Q4 2026 earnings estimates for shares of Rockwell Medical in a report issued on Monday, January 26th. HC Wainwright analyst R. Selvaraju now anticipates that the company will earn $0.01 per share for the quarter, up from their prior forecast of ($0.01). HC Wainwright has a “Buy” rating and a $2.50 price objective on the stock. The consensus estimate for Rockwell Medical’s current full-year earnings is $0.03 per share.

RMTI has been the subject of several other reports. Wall Street Zen cut Rockwell Medical from a “hold” rating to a “sell” rating in a research note on Saturday, November 15th. Weiss Ratings restated a “sell (d-)” rating on shares of Rockwell Medical in a research report on Thursday. One equities research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Rockwell Medical presently has an average rating of “Hold” and a consensus price target of $2.50.

Rockwell Medical Price Performance

Shares of RMTI stock opened at $1.09 on Tuesday. The company has a current ratio of 3.91, a quick ratio of 3.50 and a debt-to-equity ratio of 0.25. The firm’s 50 day moving average is $0.93 and its 200-day moving average is $1.11. Rockwell Medical has a 1 year low of $0.78 and a 1 year high of $2.19. The firm has a market capitalization of $42.95 million, a price-to-earnings ratio of -6.81 and a beta of 1.65.

Hedge Funds Weigh In On Rockwell Medical

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Vanguard Group Inc. grew its position in shares of Rockwell Medical by 12.3% in the 3rd quarter. Vanguard Group Inc. now owns 1,354,147 shares of the company’s stock valued at $1,625,000 after purchasing an additional 148,737 shares during the period. GSA Capital Partners LLP lifted its stake in Rockwell Medical by 635.1% in the third quarter. GSA Capital Partners LLP now owns 163,978 shares of the company’s stock valued at $197,000 after buying an additional 141,672 shares in the last quarter. Finally, Panagora Asset Management Inc. acquired a new position in shares of Rockwell Medical in the second quarter valued at approximately $41,000. Institutional investors own 23.31% of the company’s stock.

Rockwell Medical Company Profile

Rockwell Medical, Inc is a Delaware‐domiciled biopharmaceutical company focused on the development and commercialization of therapies for patients with chronic kidney disease (CKD). The company’s mission centers on addressing common complications in CKD—namely iron deficiency and secondary hyperparathyroidism—through innovative treatment approaches designed for dialysis settings.

The company’s lead product, TRIFERIC®, is an iron replacement therapy approved by the U.S. Food and Drug Administration for use in hemodialysis patients.